Prudence Kgagudi to HIV Infections
This is a "connection" page, showing publications Prudence Kgagudi has written about HIV Infections.
Connection Strength
0,439
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.
Score: 0,060
-
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLoS Pathog. 2023 06; 19(6):e1011469.
Score: 0,060
-
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms. Sci Rep. 2022 10 01; 12(1):16473.
Score: 0,057
-
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathog. 2022 09; 18(9):e1010450.
Score: 0,056
-
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat Med. 2022 09; 28(9):1924-1932.
Score: 0,056
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
Score: 0,052
-
Impaired Transplacental Transfer of Respiratory Syncytial Virus-neutralizing Antibodies in Human Immunodeficiency Virus-infected Versus -uninfected Pregnant Women. Clin Infect Dis. 2019 06 18; 69(1):151-154.
Score: 0,045
-
The Burden of Pertussis Hospitalization in HIV-Exposed and HIV-Unexposed South African Infants. Clin Infect Dis. 2016 Dec 01; 63(suppl 4):S165-S173.
Score: 0,038
-
Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines. J Virol. 2024 Jan 23; 98(1):e0147823.
Score: 0,015